IL1B and rheumatoid arthritis: The treatment downregulated the expression of the proinflammatory cytokines IL-1β, IL-6, MCP-1, and TNF-α in serum, and ameliorated synovitis and RA-related pathological hallmarks, such as inflammatory cell infiltration in synovial tissue.